Poseida therapeutics reports positive interim phase 1 results for allogeneic car-t therapy p-bcma-allo1 with high overall response rates in heavily pretreated relapsed/refractory multiple myeloma patients

Data showed a 91% orr with p-bcma-allo1 in an optimized lymphodepletion arm, including a 100% orr in bcma-naÏve patients, and an 86% orr in those who had received at least one prior bcma- and/or gprc5d-targeting treatment modality differentiated p-bcma-allo1 safety results with no dose-limiting toxicities, low rates of crs and icans all grade 2 or less and no graft vs. host disease or parkinsonism p-bcma-allo1 was recently granted regenerative medicine advanced therapy (rmat) designation from the fda and is being evaluated in a phase 1/1b clinical trial in patients with relapsed/refractory multiple myeloma  who have previously received three or more prior lines of therapy company to host webcast and conference call tomorrow at 1 p.m.
CAR Ratings Summary
CAR Quant Ranking